A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
A phase 1/2 trial of B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell in multiple myeloma, run by Shanghai AbelZeta Ltd., now recruiting.
Overview
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05521802 by Shanghai AbelZeta Ltd., with 92 participants planned, started 2022-11-11 and due to reach its primary completion in 2024-07. Interventions recorded: B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)
Shares Shanghai AbelZeta and the tag pipeline.
- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.